Evidence map›Paper›PMID 40469640›Full record

ArticleFrontiers in transplantation2025

Long-term outcomes of a case-control lung transplant cohort after SARS-CoV-2 infection.

Sandrine Hanna, Rami Hallak, Susanna M Leonard, Samantha Morrison, Sarah Peskoe, Jordan Whitson, John M Reynolds, Cameron R Wolfe, Hakim Azfar Ali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sandrine HannaDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Hospital, Durham, NC, United States.
Rami HallakDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Hospital, Durham, NC, United States.
Susanna M LeonardDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Hospital, Durham, NC, United States.
Samantha MorrisonDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, United States.
Sarah PeskoeDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, United States.
Jordan WhitsonDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Hospital, Durham, NC, United States.
John M ReynoldsDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Hospital, Durham, NC, United States.
Cameron R WolfeDivision of Infectious Diseases, Department of Medicine, Duke University Hospital, Durham, NC, United States.
Hakim Azfar AliDivision of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University Hospital, Durham, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Respiratory viruses can impact the allograft function in lung transplant recipients, but it is unknown if this occurs with SARS-CoV-2 infection. We studied the long-term outcomes of lung transplant recipients infected with SARS-CoV-2. Methods: This single-center retrospective study compared lung transplant recipients with SARS-CoV-2 between June 2020 and April 2021 with a matched control group. Within the SARS-CoV-2 cohort, univariable associations between clinical factors and outcomes were tested. Changes in pulmonary function tests were analyzed. Primary endpoints included acute cellular rejection and all-cause mortality within 12 months. Results: Fifty-three lung transplant recipients were infected with SARS-CoV-2. The median age was 64 years. 29 (54.7%) were managed outpatient, and 24 (45.3%) required hospitalization, with 13 intensive care unit admissions. All-cause mortality was 24.5%. Within the SARS-CoV-2 cohort, older age was significantly associated with all-cause mortality ( Conclusion: Long-term outcomes of SARS-CoV-2 in lung transplant recipients are widely variable. Within the SARS-CoV-2 cohort, all-cause mortality was 24.5%, and older age was significantly associated with mortality. We did not observe significant declines in FEV1 in this group.

Indexed as

acute cellular rejection (ACR)COVID-19FEV 1immune compromiselung transplantmortalitySARS-CoV-2 infection

Identifiers

PMID40469640
PMCPMC12133828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.